Analysis of the efficacy of paclitaxel combined with bevacizumab intraperitoneal instillation in common gastrointestinal malignant peritoneal effusions and screening of prognostic indicators
This study demonstrated that the combination of paclitaxel and bevacizumab is more effective and that LA, LDH, and CD4<sup>+</sup>/CD8<sup>+</sup> can predict treatment efficacy.
Authors
- Xuguang Mi
- Xianzhuo Jiang
- Yanqiu Fang
- Yucong Li (ORCID: https://orcid.org/0000-0003-4621-5579)
- Xiuying Lin
- Junjie Hou (ORCID: https://orcid.org/0000-0003-2195-771X)
- Zhiqiang Ni
- Xiao‐Nan Li
- Ying Yang (ORCID: https://orcid.org/0000-0003-0797-4353)
- Yingying Yu (ORCID: https://orcid.org/0000-0002-5623-5250)
- Ying Zhou (ORCID: https://orcid.org/0000-0003-2809-7396)
- Junzi Zhang
Institutions
- People 's Hospital of Jilin Province (CN)
- Changchun University of Chinese Medicine (CN)
Publication Details
- Journal
- Expert Review of Anticancer Therapy
- Published
- 2025-06-19
- DOI
- https://doi.org/10.1080/14737140.2025.2522251
- Primary Topic
- Intraperitoneal and Appendiceal Malignancies
- Type
- article
- Field-Weighted Citation Impact
- 0.00